About KalVista
KalVista is a company based in Cambridge (United States) founded in 2011 was acquired by Chiesi Pharmaceuticals in April 2026. KalVista has raised $13.18 million across 3 funding rounds from investors including Chiesi Pharmaceuticals, RA Capital and Longwood Fund. The company has 270 employees as of April 30, 2024. KalVista offers products and services including Sebetralstat. KalVista operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 270 as on 30 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kalvista Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$183.44 M (USD)-44.85as on Apr 30, 2025
-
EBITDA
-$192.07 M (USD)-29.7as on Apr 30, 2025
-
Total Equity Funding
$13.18 M (USD)
in 3 rounds
-
Latest Funding Round
$33 M (USD), Post-IPO
Jul 22, 2015
-
Investors
Chiesi Pharmaceuticals
& 6 more
-
Employee Count
270
as on Apr 30, 2024
-
Acquired by
Chiesi Pharmaceuticals
(Apr 29, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of KalVista
KalVista is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of KalVista
KalVista offers a comprehensive portfolio of products and services, including Sebetralstat.
Oral inhibitor targeting Factor XIIa for HAE treatment.
People of KalVista
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Sales and Marketing
9 people
Operations Team
5 people
Finance and Accounting
5 people
Software Development Team
5 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of KalVista
KalVista has successfully raised a total of $13.18M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $33 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KalVista
KalVista has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chiesi Pharmaceuticals, RA Capital and Longwood Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked |
Investor details for KalVista
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KalVista
Investment portfolio details for KalVista
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KalVista
Detailed financials for KalVista
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kalvista Comparisons
Peer comparison for KalVista
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KalVista
KalVista operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of KalVista
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kalvista
Complete news archive for KalVista
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KalVista
KalVista was founded in 2011.
KalVista is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
KalVista is a funded company, having raised a total of $13.18M across 3 funding rounds to date.
As of Apr 30, 2024, the latest employee count at KalVista is 270.
KalVista therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors through providing healthcare solutions, diversified pharmaceuticals, and drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
KalVista's top competitors include Merck, Roivant Sciences and AbbVie.
KalVista offers Sebetralstat.
Yes, KalVista is publicly traded on NASDAQ under the ticker symbol KALV.
KalVista has 7 investors. Key investors include Chiesi Pharmaceuticals, RA Capital, Longwood Fund, Venrock, and SV Health Investors.
The ticker symbol of KalVista is KALV on NASDAQ.